Scheffler P, Donecke P, de la Hamette D, Berberich R, Kramann B, Wenzel E
Abteilung für Klinische Hämostaseologie und Angiologische Ambulanz, Universität des Saarlandes, Universitätsklinikum, Homburg/Saar.
Z Gesamte Inn Med. 1987 Sep 1;42(17):492-8.
The efficacy of fibrinolysis in DVT is dependent upon the age and organization of the thrombus as well as its localization. In consequence, selective evaluation prior to determining the indication for thrombolytic therapy is just as important for therapeutic success as choosing the appropriate fibrinolytic agent. To improve the results of fibrinolysis a team of angiologists, hemostaseologists, radiologists and surgeons are cooperating in a special "thromboembolic care unit". Phlebographic criteria were defined which allow differentiation of fibrinolytic indications depending upon the site of the thrombus. Selection of the fibrinolytic agent and careful monitoring of the thrombolysis should ensure a maximum therapeutic effect with a minimum of bleeding complications. The duration of thrombolysis was established through phlebographic verification and functional tests with venous occlusion plethysmography. The cause and results of 108 cases of thrombolysis shall be presented.
纤维蛋白溶解疗法在深静脉血栓形成(DVT)中的疗效取决于血栓的年龄、机化程度及其位置。因此,在确定溶栓治疗指征之前进行选择性评估对于治疗成功而言,与选择合适的纤维蛋白溶解剂同样重要。为了提高纤维蛋白溶解疗法的效果,一组血管病学家、止血学家、放射科医生和外科医生正在一个特殊的“血栓栓塞护理单元”中开展合作。已确定了静脉造影标准,可根据血栓部位区分纤维蛋白溶解疗法的指征。选择纤维蛋白溶解剂并仔细监测溶栓过程应能确保在出血并发症最少的情况下获得最大治疗效果。溶栓持续时间通过静脉造影验证和静脉阻塞体积描记法的功能测试来确定。本文将介绍108例溶栓病例的病因及结果。